Illustrative

Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S

The New England Journal of Medicine·Feb 9

✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source

A final analysis has been conducted on the efficacy and safety of a single-dose treatment called Ad26.COV2.S. The results of this analysis are now available. The details of the findings have not been specified.

Full coverage

Association between COVID-19 vaccine efficacy and epidemic force of infection

Nature·Jan 17

Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet·Sep 13

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

The New England Journal of Medicine·Apr 21

A comprehensive analysis of the efficacy and effectiveness of COVID-19 vaccines

Frontiers·Aug 26

Quantifying how single dose Ad26.COV2.S vaccine efficacy depends on Spike sequence features

Nature·Mar 11

Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlle

The Lancet·Dec 23

Neutralizing antibody correlate of protection against severe-critical COVID-19 in the ENSEMBLE single-dose Ad26.COV2.S vaccine efficacy trial

Nature·Nov 12

Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant

The New England Journal of Medicine·Mar 16

View original report at The New England Journal of Medicine ↗

Fetching the latest headlines…